Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

NCT05804032 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

514

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Isatuximab
DRUG: Isatuximab
DRUG: Lenalidomide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

University of Heidelberg Medical Center

Collaborators

[object Object]
[object Object]
[object Object]